Compare BioNano Genomics Inc (BNGO) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Dropbox Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Dropbox Inc trades at $33.71 (market cap $7.41B). The key difference: Dropbox Inc is far larger — about 542.5× BioNano Genomics Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | DBX | |
|---|---|---|
Market Cap | $13.66M | $7.41B |
Sector | Health | Technology |
52-Week High | $4.92 | $35.00 |
52-Week Low | $1.06 | $22.06 |
Enterprise Value | $16.26M | $10.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
DBX trades at $34.59, down 0.63% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue remains steady at $2.52B for 2025, with a net income margin of 20.16%. The company raised its 2026 outlook after Q2 results, supported by core file-sync-and-share growth and AI expansion. Cash flow from operations improved to $952M in 2025, though net cash flow was negative due to financing activities.
The outlook is mixed; strong profitability and bullish analyst coverage contrast with high debt levels and negative shareholder equity. Risks include competitive pressures and reliance on sustained user growth. With 37.5% of analysts rating it a buy, the stock offers growth potential but requires monitoring of balance sheet health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
